Idorsia: Aprocitentan Partner Fails to Sign Deal as Planned (1)

Idorsia’s exclusivity agreement signed in Nov. 24 with an undisclosed party for the global rights to hypertension drug Aprocitentan has concluded without the party signing the deal, according to a statement.

• Idorsia will retain the exclusivity fee of $35 million paid in December
  • Idorsia to resume discussions with other potential partners
• Company also updates terms of selatogrel and cenerimod agreement with Viatris that will reduce Idorsia’s contribution in 2025 by $100m
  • Means Idorsia will get $250m less in future potential milestones
• Developments follow Idorsia’s announcement late on Tuesday that 79% of bondholders of its 2025 convertible bonds have ...